- Report
- August 2024
- 180 Pages
Global
From €2177EUR$2,290USD£1,829GBP
- Report
- September 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 140 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Report
- April 2024
- 160 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- September 2018
- 174 Pages
Global
From €1307EUR$1,375USD£1,098GBP
€2614EUR$2,750USD£2,196GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Report
- August 2022
- 30 Pages
Global
From €3090EUR$3,250USD£2,596GBP
- Report
- March 2024
- 397 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2614EUR$2,750USD£2,196GBP
- Report
- October 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- April 2023
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
Vraylar is a medication used to treat mental disorders such as bipolar disorder and schizophrenia. It is a once-daily oral medication that works by targeting certain receptors in the brain to help regulate mood and behavior. Vraylar is a relatively new drug, having been approved by the FDA in 2015. It is classified as an atypical antipsychotic and is used to treat both manic and depressive episodes associated with bipolar disorder. It is also used to treat schizophrenia, as well as symptoms of irritability, aggression, and mood swings associated with autism spectrum disorder.
Vraylar is marketed by Allergan, a subsidiary of AbbVie, and is available in both generic and brand-name forms. Other companies in the market include Sunovion Pharmaceuticals, Otsuka Pharmaceuticals, and Intra-Cellular Therapies. Show Less Read more
